Skip To Main Content
Barry Cooperman on Muck Rack

Barry Cooperman

As seen in: Nature
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Barry

Contact Barry, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Ataluren binds to multiple protein synthesis apparatus sites and competitively inhibits release factor-dependent termination - Nature Communications

|
By Arpan Bhattacharya, Clark Fritsch, Barry Cooperman
| Nature Verified
Abstract Genetic diseases are often caused by nonsense mutations, but only one TRID (translation readthrough inducing drug), ataluren, has been approved for clinical use. Ataluren inhibits release factor complex (RFC) termination activity, while not affecting productive binding of near-cognate ternary complex (TC, aa-tRNA.eEF1A.GTP).
Open in Who Shared Issue with article?

Probing the interaction between NatA and the ribosome for co-translational protein acetylation

|
By Robert S. Magin, Haibo Zhang, Sunbin Deng, Barry Cooperman
| PLOS
Previous studies showed that the NatA-ribosome interaction is salt dependent in vivo. We performed the same analysis with purified NatA and ribosome. We found that the same held true in our experiment. As the salt concentration increased, the interaction weakened until NatA pull down by the ribosome was undetectable ( Fig 2C ). (A) Representative Western blot of NatA/ribosome co-sedimentation assay with increasing concentration of ribosome. P stands for pellet, and S stands for supernatant.
Open in Who Shared Issue with article?
See all 2 articles